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Background: CYP2C19*2 polymorphisms have been linked to clopidogrel nonresponsiveness causing increased cardiovascular risk in coronary 
artery disease [CAD] patients. However, clinical trials in CAD patients with this polymorphism have yielded mixed results. We performed a meta-
analysis of all prospective trials to assess risk of cardiovascular events associated with CYP2C19*2 carrier state. 
Methods Pooled data from 19,503 patients [5478 carriers and 14,025 non-carriers] from 13 studies was analyzed. End points extracted were 
major adverse cardiovascular event (MACE), cardiovascular (CV) mortality, myocardial infarction (MI), stent thrombosis (ST) & major bleeding. 
Combined odds ratios (OR) and 95% confidence intervals (CI) were computed. A two-sided alpha error <0.05 was considered statistically significant. 
Mantel-Haenszel model was used for heterogeniety testing. 
Results Both groups had similar baseline characteristics. CYP2C19*2 carriers were at significantly higher risk for MACE [OR:1.18, CI:1.067-
1.32;p=0.002], CV mortality [OR:3.39,CI:1.69-6.77;p=0.001], MI [OR:1.46,CI:1.08-1.98;p=0.01], and stent thrombosis[OR:2.78,CI:1.72-4.49; 
p<0.001] compared to CYP2C19*2 non-carriers during clopidogrel therapy. Major bleeding events [OR: 0.76,CI:0.48-1.21;p=0.25] did not differ 
significantly.
Conclusion In CAD patients on clopidogrel therapy, CYP2C19*2 polymorphism is associated with significantly higher risk of cardiovascular events. 
